|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2006
Decision Resources, Inc., Sep 2006, Pages: 30
Implementation, not legislation, was the theme of the second quarter of 2006 in the major pharmaceutical markets. Enrollment in the Medicare drug benefit program far exceeded expectations. The focus in Europe is on implementing cost-containment procedures and increasing generics usage. And Japanese drug manufacturers are concerned about the threat of increased price revisions.
Get the Answers You Need to Shape Your Strategy
Enrollment in the Medicare Part D drug benefit program exceeded the expectations of the U.S. government and gained positive public opinion. Can the program maintain its popularity when beneficiaries are faced with a coverage gap and greater out-of-pocket expenses? What effect will formulary restrictions have on enrollment?
As PBMs champion the use of generic drugs, drug manufacturers must brace for increasing generics competition in the United States. The recent launch of generic simvastatin products in competition with Merck & Co.’s Zocor and other branded statins may prove to be the most difficult challenge. Can this single patent expiry effectively genericize an entire drug class?
New cost-containment strategies in Germany and Spain will greatly impact the pharmaceutical markets in those countries. How will lower reference points affect branded drugs in Germany? What will be the immediate impact in Spain of the imposition of price cuts and automatic reference pricing on older drugs?
Scope
Retiree benefits: overview of Medicare drug benefit program; the impact of increasing coinsurance for seniors in Japan; U.S. employers’ plan to restrict retirees’ health benefits.
Growth of generics market: the unprecedented impact of generic simvastatin launches; review of the dynamic growth of the generics market in France.
Cost-containment programs: overview of several European countries’ initiatives to curb drug expenditures.
Outlook: our assessment of the implications of these events on the drug industry in the major pharmaceutical markets.
Also available
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Customers who bought this item also bought
Progress Report on the Medicare Prescription Drug Benefit
Drug Benefit Trends in the United States
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
Key Markets in Medicare Part D
GenericHandbook - A Guide to the Generic Drug Industry in the US
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Generic Drug Market in Canada
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
New Dynamics and Challenges in the Generics Market 2007
Changing Role of Medicare and its Impact on Pharmaceutical Industry
Pharmaceutical Pricing and Reimbursement in the United States, 2008
|
|
|
|
